This study is checking the long-term safety of repeated doses of an investigational drug called STK-001 for people with Dravet syndrome, a severe form of epilepsy. It is open to about 60 patients who have already safely received the drug in earlier studies. Researchers will also …
Phase: PHASE2 • Sponsor: Stoke Therapeutics, Inc • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC